Study on the Mechanism of Gardenia Bean Soup for Gastroesophageal Reflux Disease Based on Network Pharmacology

DOI: https://doi.org/10.62517/jmhs.202605402

Author(s)

Yunxiao Wu, Shuting Wang, Chenyue Xu, Xiaoming Wang*

Affiliation(s)

School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China * Corresponding Author

Abstract

Gastroesophageal reflux disease (GERD) is highly prevalent, and Gardenia bean soup is traditionally used to clear and disperse depressed heat; therefore, this study employs network pharmacology to explore its therapeutic molecular mechanisms and provide evidence for the modernization of traditional Chinese medicine. Drug and disease targets were obtained from TCMSP and other databases, and their intersection was used to construct a "drug-component-target" network, with a PPI network constructed using STRING and Cytoscape, GO and KEGG enrichment analysis performed with DAVID, and molecular docking carried out with Autodock. A total of 89 active components and 179 intersection targets were screened, with core targets including TP53, TNF, STAT3, AKT1, and others; GO and KEGG enrichment yielded numerous items and signaling pathways, and molecular docking showed that most components bound strongly to the targets. These findings suggest that Gardenia bean soup may regulate the PI3K-Akt/NF-κB and other pathways through components such as quercetin, acting on targets including STAT3, AKT1, IL1B, BCL2, MMP2, MMP9, PTEN, and IGF1, thereby exerting anti-inflammatory and mucosal repair effects and reflecting the characteristics of multi-component, multi-target, and multi-pathway action.

Keywords

Network Pharmacology; Gardenia Bean Soup; Gastroesophageal Reflux; Core Targets; Molecular Docking

References

[1] Sun, P. (2012). The treatment of gastro-oesophageal reflux disease with traditional Chinese medicine. Journal of Chinese Medicine, (140), 48. [2] Ren, L., Fan, Y., Luo, H., Zhang, Y., Wang, Y., & Li, X. (2024). PACAP/VIP in the prefrontal cortex mediates the rapid antidepressant effects of zhizichi decoction. Journal of Ethnopharmacology, 335, 118638. [3] Huang, J., Lin, S., Lin, L., Zheng, J., Chen, Z., Xie, J., & Liu, X. (2025). Multi-pathway mechanisms of Liujunzi decoction in promoting glioma apoptosis and reversing drug resistance: Network pharmacology and experimental validation. Frontiers in Pharmacology, 16, 1682550. [4] Zhang, R., Yang, Z., Pan, X., Liu, Y., Huang, Q., Song, Z., Yao, Q., Li, D., & Zhang, Y. (2025). The positive role of Chinese herbal medicine as an adjunctive therapy for refractory gastroesophageal reflux disease: A systematic review and network meta-analysis. Medicine, 104(21), e42565. [5] Liu, J., Huang, J., Zhang, B., Yin, X., Lv, M., Liu, Z., Wang, F., & Tang, X. (2022). Treatment of the gastroesophageal reflux disease with Chinese herbal medicine (Banxia Xiexin decoction): Evidence from meta-analysis. Evidence-Based Complementary and Alternative Medicine, 2022, 1500660 [6] Wang, F., Zhang, B., Yin, X., Liu, Z., Lv, M., & Tang, X. (2020). Efficacy of Chinese herbal formula Sini Zuojin decoction in treating gastroesophageal reflux disease: Clinical evidence and potential mechanisms. Frontiers in Pharmacology, 11, 76. [7] Jiang, X., Cheng, H., Zhang, N., Li, Y., Wang, Y., & Chen, J. (2022). Study on syndrome rules of stagnated heat in liver and stomach of non-erosive reflux disease based on microecology of tongue coating. Medicine, 101(44), e31618. [8] Lawrence, T. (2009). The nuclear factor NF-κB pathway in inflammation. Cold Spring Harbor Perspectives in Biology, 1(6), a001651. [9] Kim, S. H., Shin, M. R., Lee, A. R., Kim, D. H., Park, H. J., & Roh, S. S. (2020). Improvement of inflammation through antioxidant pathway of Gardeniae Fructus 50% EtOH extract (GE) from acute reflux esophagitis rats. BioMed Research International, 2020, 4826176. [10] Liu, X., Ma, Y., He, L., Zhang, H., Li, J., & Wang, Y. (2016). Effects of Zhizi Ganchen Chi Decoction, Dahuang Huanglian Xiexin Decoction and their combined formula on gastrointestinal hormones in rats with reflux esophagitis. Chinese Journal of Basic Medicine in Traditional Chinese Medicine, 22(6), 768-770. [11] Hämäläinen, M., Nieminen, R., Vuorela, P., Heinonen, M., & Moilanen, E. (2007). Anti-inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-κB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-κB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators of Inflammation, 2007, 45673. [12] Guo, Z., Tang, Y., Li, M., Yang, L., Liu, L., Li, P., & Liu, S. (2025). Integrated transcriptomic and metabolomic analyses reveal the mechanism by which quercetin inhibits reflux esophagitis in rats. PLoS One, 20(5), e0321959. [13] Deng, T., Zhang, N., Liu, Y., Li, J., & Wang, H. (2021). Daidzein ameliorates experimental acute reflux esophagitis in rats via regulation of cytokines. Die Pharmazie—An International Journal of Pharmaceutical Sciences, 76(2-3), 84-91. [14] Li, Y., Pham, V., Bui, M., Song, L., & Wu, J. (2020). Preventative and therapeutic potential of flavonoids in peptic ulcers. Molecules, 25(20), 4626. [15] Wang, W., & Ma, X. (2020). miR-210 promotes malignant progression in patients with recurrent reflux esophagitis by activating IL-6/STAT3 inflammatory signaling pathway. Chinese Journal of Gastroenterology and Hepatology, 29(6), 660–664. [16] Song, M., Bode, A. M., Dong, Z., & Lee, M. H. (2019). AKT as a therapeutic target for cancer. Cancer Research, 79(6), 1019-1031. [17] Redston, M., Noffsinger, A., Kim, A., Akarca, F. G., Rara, M., Stapleton, D., Nowden, L., Lash, R., Bass, A. J., & Stachler, M. D. (2022). Abnormal TP53 predicts risk of progression in patients with Barrett's esophagus regardless of a diagnosis of dysplasia. Gastroenterology, 162(2), 468-481. [18] Zheng, J., & Tao, L. (2025). Multidimensional mechanisms and therapies underlying gastroesophageal reflux disease: Focus on immunity, signaling pathways, and the microbiota-gut-brain axis. Frontiers in Immunology, 16, 1629944. [19] Duh, G., Mouri, N., Warburton, D., & Thomas, D. W. (2000). EGF regulates early embryonic mouse gut development in chemically defined organ culture. Pediatric Research, 48(6), 794-802. [20] Luo, Q., Du, R., Liu, W., Zhang, H., Chen, Y., & Wang, J. (2022). PI3K/Akt/mTOR signaling pathway: Role in esophageal squamous cell carcinoma, regulatory mechanisms and opportunities for targeted therapy. Frontiers in Oncology, 12, 852383. [21] Dumitru, C. D., Ceci, J. D., Tsatsanis, C., Kontoyiannis, D., Stamatakis, K., Lin, J. H., Patriotis, C., Jenkins, N. A., Copeland, N. G., Kollias, G., & Tsichlis, P. N. (2009). Akt-mediated regulation of NFκB and the essentialness of NFκB activity for oncogenic transformation induced by Akt. International Journal of Cancer, 125(12), 2863-2870. [22] Tamizhselvi, R., Sun, J., Koh, Y. H., Moochhala, S., & Bhatia, M. (2009). Effect of hydrogen sulfide on the phosphatidylinositol 3-kinase-protein kinase B pathway and on caerulein-induced cytokine production in isolated mouse pancreatic acinar cells. Journal of Pharmacology and Experimental Therapeutics, 329(3), 1166-1177. [23] Zhuang, J. Y., Chen, Z. Y., Zhang, T., Liu, J., Li, Y., & Wang, H. (2017). Effects of different ratio of n-6/n-3 polyunsaturated fatty acids on the PI3K/Akt pathway in rats with reflux esophagitis. Medical Science Monitor, 23, 421-430. [24] Schmidt, A. M., Yan, S. D., Yan, S. F., & Stern, D. M. (2001). The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. Journal of Clinical Investigation, 108(7), 949-955. [25] Farhadi, A., Fields, J., Banan, A., & Keshavarzian, A. (2002). Reactive oxygen species: Are they involved in the pathogenesis of GERD, Barrett's esophagus, and the latter's progression toward esophageal cancer? American Journal of Gastroenterology, 97(1), 22-26. [26] Zhou, S., Wang, G., & Zhang, W. (2018). Effect of TLR4/MyD88 signaling pathway on sepsis-associated acute respiratory distress syndrome in rats, via regulation of macrophage activation and inflammatory response. Experimental and Therapeutic Medicine, 15(4), 3376-3384.